Everything we've seen

1. ·Jun 29, 3:49 PMstreamnews

   This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

   Parabilis Medicines is ambitious, but it has Regeneron on its side already.

2. ·Jun 29, 3:49 PMstreamnews

   RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why

   Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]

3. ·Jun 29, 3:49 PMstreamnews

   Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

   Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with “generalized myasthenia gravis” who are anti-acetylcholine receptor antibody-positive. The company […]

4. ·Jun 29, 3:34 PMstreamnews

   This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

   Parabilis Medicines is ambitious, but it has Regeneron on its side already.

5. ·Jun 29, 3:34 PMstreamnews

   RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why

   Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]

6. ·Jun 29, 3:34 PMstreamnews

   Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

   Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with “generalized myasthenia gravis” who are anti-acetylcholine receptor antibody-positive. The company […]

7. ·Jun 29, 3:18 PMstreamnews

   This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

   Parabilis Medicines is ambitious, but it has Regeneron on its side already.

8. ·Jun 29, 3:18 PMstreamnews

   RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why

   Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]

9. ·Jun 29, 3:18 PMstreamnews

   Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

   Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with “generalized myasthenia gravis” who are anti-acetylcholine receptor antibody-positive. The company […]

10. ·Jun 29, 3:04 PMstreamnews

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

11. ·Jun 29, 3:04 PMstreamnews

    RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]

12. ·Jun 29, 3:04 PMstreamnews

    Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with “generalized myasthenia gravis” who are anti-acetylcholine receptor antibody-positive. The company […]

13. ·Jun 29, 2:49 PMstreamnews

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

14. ·Jun 29, 2:49 PMstreamnews

    RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]

15. ·Jun 29, 2:49 PMstreamnews

    Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with “generalized myasthenia gravis” who are anti-acetylcholine receptor antibody-positive. The company […]

16. ·Jun 29, 2:34 PMstreamnews

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

17. ·Jun 29, 2:34 PMstreamnews

    RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]

18. ·Jun 29, 2:34 PMstreamnews

    Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with “generalized myasthenia gravis” who are anti-acetylcholine receptor antibody-positive. The company […]

19. ·Jun 29, 2:19 PMstreamnews

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

20. ·Jun 29, 2:19 PMstreamnews

    RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]

21. ·Jun 29, 2:19 PMstreamnews

    Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with “generalized myasthenia gravis” who are anti-acetylcholine receptor antibody-positive. The company […]

22. ·Jun 29, 2:04 PMstreamnews

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

23. ·Jun 29, 2:04 PMstreamnews

    RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]

24. ·Jun 29, 2:04 PMstreamnews

    Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with “generalized myasthenia gravis” who are anti-acetylcholine receptor antibody-positive. The company […]

25. ·Jun 29, 1:49 PMstreamnews

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

26. ·Jun 29, 1:49 PMstreamnews

    RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]

27. ·Jun 29, 1:34 PMstreamnews

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

28. ·Jun 29, 1:19 PMstreamnews

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

29. ·Jun 29, 1:03 PMstreamnews

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

30. ·Jun 29, 12:48 PMstreamnews

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

31. ·Jun 29, 12:33 PMstreamnews

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

32. ❖Jun 29, 5:45 AMnewsvia finnhub

    Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side

    The week closed with the Strait of Hormuz still bleeding headlines and crude already down nine percent. Sunday, Washington and Tehran said they were standing down and heading to Doha. Whether that holds is anyone's guess, but for one trading day, at least, the market gets to price the calmer outcome.

33. ❖Jun 28, 3:58 PMnewsvia finnhub

    Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with “generalized myasthenia gravis” who are anti-acetylcholine receptor antibody-positive. The company […]

34. ❖Jun 28, 10:01 AMnewsvia finnhub

    RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]

35. ❖Jun 27, 8:20 PMnewsvia finnhub

    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

    Parabilis Medicines is ambitious, but it has Regeneron on its side already.

36. ?Jun 26, 6:04 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $632.90 < MA150 $729.66 (-13.3%), MA falling, 22.9% off 52w high, vol 0.95× avg

37. ❖Jun 26, 1:01 PMnewsvia finnhub

    Why BMO's Siegerman says Merck is a top healthcare stock pick

    CNBC’s “Closing Bell Overtime” team discusses where the best opportunities are in pharma and biotech stocks with Evan Seigerman, head of healthcare research at BMO Capital Markets.

38. ✓Jun 26, 11:30 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    REGN is up 2.61% today with ~255 minutes remaining, giving ample time for further movement. The move itself represents meaningful institutional flow with no obvious catalyst visible in headlines (the Beam Therapeutics note is unrelated). Macro context shows 10Y inflation expectations running ~1.9σ below trend, which is modestly supportive for long-duration growth/biotech names like REGN as it implies lower real rate pressure. There is no negative REGN-specific news to explain a fade. However, the setup lacks strong positive catalysts to drive conviction above 0.65 — no explicit REGN headline driving the move, and without knowing volume dynamics or whether this is morning-high momentum that has since stalled, I cannot assign high confidence. The absence of a fade signal combined with supportive macro and time remaining tilts this to modest continuation probability. Standard momentum bias applies: intraday moves of this magnitude more often continue than reverse absent a specific reversal trigger.

39. ❖Jun 26, 10:34 AMnewsvia finnhub

    Here's Why You Should Add Kiniksa Stock to Your Portfolio Now

    KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.

40. ❖Jun 26, 9:10 AMnewsvia finnhub

    CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low

    https://www.cdc.gov/ebola/situation-summary/index.html

41. ❖Jun 26, 4:40 AMnewsvia finnhub

    Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade)

    Beam Therapeutics could have a moat around its business due to Risto-cel showing competitive efficacy. See why BEAM stock is downgraded to a hold.

42. ▢Jun 25, 8:00 PMjournal

    Agent 7 — Day Trader opened long 4 @ $636.33

43. ▣Jun 25, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 4 @ $631.72 (-$18.44)

    EOD forced close — day trader never carries overnight

44. ❖Jun 25, 4:05 PMnewsvia finnhub

    Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

    TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s websi

45. ❖Jun 25, 11:11 AMnewsvia finnhub

    Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?

    Kymera Therapeutics shares catapulted Thursday after the company wrapped enrollment in an eczema study six months ahead of expectations.

46. ❖Jun 25, 10:13 AMnewsvia finnhub

    Is AbbVie a Buy After Its Purchase of Apogee?

    The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

47. ?Jun 24, 6:06 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

48. !Jun 24, 6:06 PMsignalseverity 0.15

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

49. ?Jun 24, 6:01 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $623.41 < MA150 $730.84 (-14.7%), MA falling, 24.1% off 52w high, vol 0.41× avg

50. ❖Jun 24, 2:09 PMnewsvia finnhub

    Will Priority-Reviewed Quarterly siRNA gMG Therapy Change Regeneron Pharmaceuticals' (REGN) Narrative?

    Regeneron Pharmaceuticals recently reported that both the U.S. FDA and EMA have accepted regulatory applications for cemdisiran to treat adult anti-AChR antibody-positive generalized myasthenia gravis, with the FDA granting Priority Review and a target action date in November 2026. If approved, cemdisiran would be the first siRNA therapy for gMG and the only option given subcutaneously just four times a year, potentially reshaping treatment convenience in this rare autoimmune disease. We’ll...

51. ❖Jun 23, 2:24 PMnewsvia finnhub

    Regeneron's Applications for gMG Drug Accepted by FDA and EMA

    Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.

52. ❖Jun 23, 9:50 AMnewsvia finnhub

    Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?

    AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.

53. ❖Jun 23, 8:55 AMnewsvia finnhub

    Viatris Soared 54%: Time To Be More Careful (Rating Downgrade)

    Viatris Inc. hits a 52-week high, driven by a strong late-stage pipeline, but shares corrected on Effexor sales decline. Click for this VTRS update.

54. ❖Jun 23, 3:05 AMnewsvia finnhub

    2 Underrated Weight Loss Stocks to Buy and Hold

    They look well-positioned to grab a slice of the fast-growing anti-obesity market.

55. ❖Jun 23, 12:41 AMnewsvia finnhub

    Wells Fargo Maintains Overweight on AbbVie (ABBV), Sees Value in Apogee Acquisition

    With a 5-Year Average Dividend Growth Rate of 6.33%, AbbVie Inc. (NYSE:ABBV) is included among the Top 11 Dividend Kings to Buy for Safe Dividend Growth. On June 22, Wells Fargo maintained an Overweight rating on AbbVie Inc. (NYSE:ABBV). It also set a $260 price target on the shares. The firm said AbbVie’s reported bid […]

56. ?Jun 22, 7:21 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

57. !Jun 22, 7:21 PMsignalseverity 0.16

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

58. ❖Jun 22, 6:14 PMnewsvia finnhub

    Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer

    On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.

59. ?Jun 22, 6:01 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 4: close $612.54 < MA150 $731.82 (-16.3%), MA falling, 25.4% off 52w high, vol 1.73× avg

60. ?Jun 22, 6:01 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $612.54 < MA150 $731.82 (-16.3%), MA falling, 25.4% off 52w high, vol 1.73× avg

61. ?Jun 22, 6:01 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $612.54 < MA150 $731.82 (-16.3%), MA falling, 25.4% off 52w high, vol 1.73× avg

62. ❖Jun 22, 2:59 PMnewsvia finnhub

    AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree

    The $135.11 per share cash offer for Apogee carries a 49% premium

63. ?Jun 22, 10:46 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is down 2.19% today with no clear catalyst visible in recent headlines — the news flow is entirely unrelated to REGN (AbbVie/Apogee deal, a conference announcement, and a cemdisiran FDA/EMA submission for a competitor). The absence of a specific REGN-negative catalyst suggests this could be sector rotation or sympathy selling within biotech/immunology given AbbVie's large M&A move reshuffling capital. The macro backdrop (5Y inflation expectations running 1.5σ below trend) is mildly risk-supportive and not a direct headwind for large-cap biotech. With 299 minutes remaining (nearly a full afternoon session), there is ample time for the move to continue or reverse. The 2.19% decline is meaningful and reflects real selling pressure, but without a strong directional catalyst or clear technical breakdown evidence, this is a borderline read. The AbbVie/Apogee deal could modestly weigh on REGN as a peer in the immunology space (competitive landscape narrative), providing a soft fundamental lean toward continuation. Overall, slight lean toward continuation of the downside move, but confidence is low — probability just above 0.5.

64. !Jun 22, 10:46 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    REGN is down 2.19% today with no clear catalyst visible in recent headlines — the news flow is entirely unrelated to REGN (AbbVie/Apogee deal, a conference announcement, and a cemdisiran FDA/EMA submission for a competitor). The absence of a specific REGN-negative catalyst suggests this could be sector rotation or sympathy selling within biotech/immunology given AbbVie's large M&A move reshuffling capital. The macro backdrop (5Y inflation expectations running 1.5σ below trend) is mildly risk-supportive and not a direct headwind for large-cap biotech. With 299 minutes remaining (nearly a full afternoon session), there is ample time for the move to continue or reverse. The 2.19% decline is meaningful and reflects real selling pressure, but without a strong directional catalyst or clear technical breakdown evidence, this is a borderline read. The AbbVie/Apogee deal could modestly weigh on REGN as a peer in the immunology space (competitive landscape narrative), providing a soft fundamental lean toward continuation. Overall, slight lean toward continuation of the downside move, but confidence is low — probability just above 0.5.

65. ❖Jun 22, 10:23 AMnewsvia finnhub

    Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics

    AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.

66. ❖Jun 22, 9:35 AMnewsvia finnhub

    Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?

    SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.

67. ❖Jun 22, 8:23 AMnewsvia finnhub

    AbbVie’s $10.9 Billion Apogee Therapeutics Buyout Protects Its Immunology Crown

    AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.

68. ❖Jun 22, 8:00 AMnewsvia finnhub

    Questex’s DPHARM Announces Senior Leadership and Keynotes for the 16th Annual Conference

    BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- DPHARM, the leading innovation event for clinical trial operation executives, announces the 16th annual conference agenda including its senior leadership and keynotes. DPHARM which is now part of Questex’s Fierce Life Sciences, takes place September 15-16, 2026, at the Sheraton Boston Hotel. The first line up of senior level clinical operation executives include: Jennifer Sheller, SVP, Head of Global Clinical Trial Operations, Global Clinical Development

69. ❖Jun 22, 7:00 AMnewsvia finnhub

    Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

    Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target action date in November 2026; European Commission decision anticipated in the second half of 2027 TARRYTOWN, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)

70. ❖Jun 22, 3:08 AMnewsvia finnhub

    Regeneron Pharmaceuticals Announces That Both The FDA And EMA Have Accepted Regulatory Applications For Cemdisiran To Treat Adult Patients With Generalized Myasthenia Gravis Who Are Anti-Acetylcholine Receptor Antibody-Positive

    The FDA will review the New Drug Application (NDA) under Priority Review with a target action date in November 2026, following use of a Priority Review Voucher. A decision from the European Commission is anticipated in

71. ❖Jun 20, 11:22 AMnewsvia finnhub

    Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

    Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.

72. ❖Jun 19, 10:56 AMnewsvia finnhub

    Is Sanofi (SNY) A Good Stock To Buy Now?

    Is SNY a good stock to buy? We came across a bullish thesis on Sanofi on r/ValueInvesting by stefanliemawan. In this article, we will summarize the bulls’ thesis on SNY. Sanofi’s share was trading at $42.38 as of June 18th. SNY’s trailing and forward P/E were 18.43 and 8.44 respectively according to Yahoo Finance. Sanofi engages in […]

73. ❖Jun 19, 3:00 AMnewsvia finnhub

    Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?

    CytomX Therapeutics Inc. (NASDAQ:CTMX) is one of the best growth stocks under $30 to buy now. On June 3, CytomX expanded its research collaboration with Regeneron to develop next-gen conditionally-activated bispecific cancer therapies. By combining CytomX’s PROBODY masking platform with Regeneron’s Veloci-Bi technology, the partnership aims to create treatments that remain inactive until reaching the […]

74. ❖Jun 18, 8:56 PMnewsvia finnhub

    How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story

    While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.

75. ?Jun 18, 6:21 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

76. !Jun 18, 6:21 PMsignalseverity 0.16

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

77. ❖Jun 18, 1:45 AMnewsvia finnhub

    Obama Center launch brings Democratic political glitterati to Chicago ahead of crucial elections

    Political elites, White House alums, donors and business leaders will converge on Chicago on Thursday to commemorate the launch of the Obama Presidential Center.

78. ?Jun 17, 6:05 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

79. !Jun 17, 6:05 PMsignalseverity 0.17

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

80. ❖Jun 17, 6:55 AMnewsvia finnhub

    Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program

    Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and streamlines DR program.

81. ❖Jun 17, 5:00 AMnewsvia finnhub

    3 Profitable Stocks We Think Twice About

    Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

82. ?Jun 16, 6:05 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

83. !Jun 16, 6:05 PMsignalseverity 0.16

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

84. ?Jun 15, 6:05 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

85. !Jun 15, 6:05 PMsignalseverity 0.16

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

86. ❖Jun 15, 12:49 PMnewsvia finnhub

    Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First

    Sanofi looks compelling with strong fundamentals and a robust pipeline. Click for this updated look at SNY stock and why I remain strongly bullish.

87. ❖Jun 15, 12:45 PMnewsvia finnhub

    Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

88. ❖Jun 12, 11:10 PMnewsvia finnhub

    Regeneron Broadens Pipeline With Ebola Antibody Trials And Bispecific Cancer Bets

    World Health Organization prioritizes Regeneron’s maftivimab for clinical trials targeting Bundibugyo ebolavirus as part of the global Ebola emergency response. Regeneron Pharmaceuticals (NasdaqGS:REGN) expands its collaboration with CytomX to develop conditionally activated bispecific cancer therapies. For Regeneron Pharmaceuticals (NasdaqGS:REGN), these updates highlight the company’s activity in both infectious disease and oncology. The World Health Organization’s focus on maftivimab...

89. ?Jun 12, 6:04 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

90. ❖Jun 12, 10:30 AMnewsvia finnhub

    Regeneron Pharmaceuticals, Inc. (REGN) Shareholder/Analyst Call - Slideshow

    2026-06-12. The following slide deck was published by Regeneron Pharmaceuticals, Inc.

91. ❖Jun 12, 9:48 AMnewsvia finnhub

    IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

    Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.

92. ❖Jun 12, 6:30 AMnewsvia finnhub

    REGN (NASDAQ:REGN) Presents a Classic Value Opportunity with Strong Fundamentals

    Regeneron Pharmaceuticals (REGN) shows strong value with a P/E of 13.4, solid financial health, and double-digit growth potential, making it a compelling pick for value investors.

93. ?Jun 11, 6:04 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

94. !Jun 11, 6:04 PMsignalseverity 0.16

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

95. ❖Jun 11, 2:21 PMnewsvia finnhub

    Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now?

    Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $616.18 as of June 9th. REGN’s trailing and forward P/E were 15.51 and 14.16 respectively according to Yahoo […]

96. ❖Jun 11, 7:29 AMnewsvia finnhub

    Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy

    A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.

97. ?Jun 10, 8:06 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

98. !Jun 10, 8:06 PMsignalseverity 0.18

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

99. ❖Jun 10, 3:52 PMnewsvia finnhub

    Parabilis Raises Nearly $745 Million As IPO Demand Surges

    Cancer drug developer priced above range after demand reportedly reached about 10 times available shares.

100. ❖Jun 10, 12:21 PMnewsvia finnhub

     Parabilis Medicines raises record $670 million in biotech IPO

     The Cambridge, Massachusetts-based biotech priced 33.5 million shares at $20 each, topping the $625 million raised by Kailera Therapeutics in April

101. ❖Jun 10, 7:06 AMnewsvia finnhub

     Parabilis sets a record with a $670M biotech IPO

     The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.

102. ?Jun 9, 6:05 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

103. !Jun 9, 6:05 PMsignalseverity 0.18

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

104. ❖Jun 9, 1:41 PMnewsvia finnhub

     Regeneron’s (REGN) Antibody Therapy Gains WHO Support During Ebola Outbreak

     Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks to buy with highest upside potential. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on May 28 that maftivimab has been recommended by the World Health Organization’s (WHO) Therapeutics Advisory Group to be prioritized for evaluation in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab is the most […]

105. ?Jun 9, 9:45 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     REGN is up 2.22% with 360 minutes remaining — a full session still ahead, giving ample time for continuation. The move is meaningful and represents real flow/conviction without an obvious catalyst, suggesting possible institutional accumulation or sector rotation into biotech/defensives. The macro backdrop (T10Y2Y at 2.0σ below trend) reflects a flattening/mild inversion environment that tends to favor defensive and healthcare names like REGN as investors de-risk. No news headlines are present, which is neutral per guidance. No reversal signal is apparent — the stock is holding gains mid-session rather than fading off highs. However, the absence of a clear catalyst and no volume data to confirm strength keeps conviction moderate. With bounded risk (tight stop at -1.5%, target +3%, forced close at 3:45 PM) and full session remaining, the risk/reward favors a modest continuation bias.

106. !Jun 9, 9:45 AMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     REGN is up 2.22% with 360 minutes remaining — a full session still ahead, giving ample time for continuation. The move is meaningful and represents real flow/conviction without an obvious catalyst, suggesting possible institutional accumulation or sector rotation into biotech/defensives. The macro backdrop (T10Y2Y at 2.0σ below trend) reflects a flattening/mild inversion environment that tends to favor defensive and healthcare names like REGN as investors de-risk. No news headlines are present, which is neutral per guidance. No reversal signal is apparent — the stock is holding gains mid-session rather than fading off highs. However, the absence of a clear catalyst and no volume data to confirm strength keeps conviction moderate. With bounded risk (tight stop at -1.5%, target +3%, forced close at 3:45 PM) and full session remaining, the risk/reward favors a modest continuation bias.

107. ?Jun 8, 6:26 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

108. !Jun 8, 6:26 PMsignalseverity 0.19

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

109. ?Jun 8, 6:06 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

110. !Jun 8, 6:06 PMsignalseverity 0.19

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

111. ❖Jun 8, 3:05 PMnewsvia finnhub

     Top S&P500 movers in Monday's session

     Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

112. ❖Jun 8, 2:07 PMnewsvia finnhub

     Regeneron CEO Leonard Schleifer on the power of the Constitution

     Regeneron CEO Leonard Schleifer reflects on America's tradition of innovation and explains how 250-year-old constitutional protections for patents helped lay the foundation for generations of scientific discovery.

113. ❖Jun 8, 1:38 PMnewsvia finnhub

     Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

     Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 2:00 PM EDTCompany ParticipantsRyan Crowe -...

114. ❖Jun 8, 1:27 PMnewsvia finnhub

     Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come

     Emergent BioSolutions remains under significant pressure, with persistent revenue, margin, and earnings declines. Learn more about EBS stock here.

115. ❖Jun 7, 10:48 PMnewsvia finnhub

     Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities

     Regeneron's EYLEA HD US sales surged 52% in Q1 2026, offsetting competitive pressures and patient switching within the EYLEA franchise. See why REGN is a Buy.

116. ❖Jun 5, 2:22 PMnewsvia finnhub

     A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results

     Regeneron Pharmaceuticals (REGN) has been back in focus after expanding its cancer therapy partnership with CytomX Therapeutics, a deal with up to $4b in potential milestones, alongside highly favorable Lynozyfic trial results in light chain amyloidosis. See our latest analysis for Regeneron Pharmaceuticals. Despite the Oncology headlines, the stock’s recent momentum has cooled, with the 30 day share price return down 10.47% and the 90 day share price return down 17.26%, even as the 1 year...

117. ?Jun 4, 6:03 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

118. !Jun 4, 6:03 PMsignalseverity 0.18

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

119. ?Jun 3, 10:37 AMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

120. !Jun 3, 10:37 AMsignalseverity 0.20

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

121. ?Jun 3, 10:36 AMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

122. !Jun 2, 7:01 AMsignal

     Agent 6 — Options Momentum — insufficient_capital

123. ?Jun 1, 6:03 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

124. !Jun 1, 6:03 PMsignalseverity 0.22

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

125. !Jun 1, 6:02 PMsignal

     Agent 6 — Options Momentum — insufficient_capital

126. ✓Jun 1, 7:03 AMdecisionacted

     Agent 5 — Dip Buyer (Evolving) — decide: buy

     Net signal score: +2. REGN is down ~19.9% from its 30-day high — a meaningful drop (≥15%) that qualifies as a mean-reversion candidate (+1). No earnings in the visible window provides a clean 90-day runway (+1). The sector (XLV) is underperforming the broader market on both 5d and 30d bases, suggesting the drop is partially sector-wide rather than purely idiosyncratic (+1). However, macro context is modestly mixed: VIX is low (19th percentile, neutral), the 10Y at 4.45% is near but just under the 4.5% headwind threshold (neutral), and the 2s10s is positive (+0.46pp, not inverted). The only news is a mildly positive EMA review acceptance for Otarmeni. No insider activity, no options flow, and no SEC filings limit signal clarity. Anchoring at the ~57% base rate for a fundamentally unimpaired large-cap biotech recovering a 10%+ dip within 90 days, the net +2 score (with no hard vetoes) supports a modest upward adjustment to ~0.55-0.58, tempered by the lack of confirming insider or options signals.

127. ✓May 29, 6:03 PMdecisionacted

     Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

     Wanted to buy but only $29.69 cash available; close=$621.66.

128. ?May 29, 7:02 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $3.04 cash available; close=$621.52.

129. !May 29, 7:02 AMsignal

     Agent 5 — Dip Buyer (Evolving) — insufficient_capital

     Wanted to buy but only $12.25 cash available; close=$621.66.

130. ✓May 29, 7:01 AMdecisionacted

     Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

     Wanted to buy but only $29.69 cash available; close=$621.66.

131. ?May 28, 6:01 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $12.25 cash available; close=$621.66.

132. !May 28, 6:01 PMsignal

     Agent 5 — Dip Buyer (Evolving) — insufficient_capital

     Wanted to buy but only $1.29 cash available; close=$627.74.

133. ?May 28, 6:01 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     With no negative news headlines or recent SEC filings to explain the ~16% drop from the 30-day high, the decline appears more likely driven by macro/sector rotation rather than company-specific deterioration. REGN is a fundamentally strong large-cap biotech with durable revenue streams (Dupixent, Eylea) and a solid balance sheet, suggesting no structural impairment. However, the macro backdrop shows elevated 10-year inflation expectations (~2.5σ above trend), which pressures long-duration growth assets like biotech, creating a headwind for a near-term rebound to the prior high.

134. !May 28, 6:01 PMsignalseverity 0.19

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     With no negative news headlines or recent SEC filings to explain the ~16% drop from the 30-day high, the decline appears more likely driven by macro/sector rotation rather than company-specific deterioration. REGN is a fundamentally strong large-cap biotech with durable revenue streams (Dupixent, Eylea) and a solid balance sheet, suggesting no structural impairment. However, the macro backdrop shows elevated 10-year inflation expectations (~2.5σ above trend), which pressures long-duration growth assets like biotech, creating a headwind for a near-term rebound to the prior high.

135. ?May 28, 6:01 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

     Wanted to buy but only $29.69 cash available; close=$621.66.

136. !May 28, 6:01 PMsignal

     Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

     Wanted to buy but only $51.79 cash available; close=$627.74.

137. ?May 28, 7:01 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $1.29 cash available; close=$627.74.

138. !May 28, 7:01 AMsignal

     Agent 5 — Dip Buyer (Evolving) — insufficient_capital

     Wanted to buy but only $0.00 cash available; close=$627.74.

139. ?May 28, 7:01 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

     Wanted to buy but only $51.79 cash available; close=$627.74.

140. !May 28, 7:01 AMsignal

     Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

     Wanted to buy but only $50.13 cash available; close=$627.74.

141. ?May 27, 6:01 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $0.00 cash available; close=$627.74.

142. ?May 27, 6:01 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     With no negative news headlines or recent SEC filings to explain the ~16% drop from the 30-day high, the decline appears more likely driven by macro/sector rotation rather than company-specific deterioration. REGN is a fundamentally strong large-cap biotech with durable revenue streams (Dupixent, Eylea) and a solid balance sheet, suggesting no structural impairment. However, the macro backdrop shows elevated 10-year inflation expectations (~2.5σ above trend), which pressures long-duration growth assets like biotech, creating a headwind for a near-term rebound to the prior high.

143. !May 27, 6:01 PMsignalseverity 0.18

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     With no negative news headlines or recent SEC filings to explain the ~16% drop from the 30-day high, the decline appears more likely driven by macro/sector rotation rather than company-specific deterioration. REGN is a fundamentally strong large-cap biotech with durable revenue streams (Dupixent, Eylea) and a solid balance sheet, suggesting no structural impairment. However, the macro backdrop shows elevated 10-year inflation expectations (~2.5σ above trend), which pressures long-duration growth assets like biotech, creating a headwind for a near-term rebound to the prior high.

144. !May 27, 6:01 PMsignal

     Agent 5 — Dip Buyer (Evolving) — insufficient_capital

     Wanted to buy but only $0.00 cash available; close=$634.62.

145. ?May 27, 6:01 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

     Wanted to buy but only $50.13 cash available; close=$627.74.

146. !May 27, 6:01 PMsignal

     Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

     Wanted to buy but only $21.36 cash available; close=$634.62.

147. ?May 27, 7:01 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $0.00 cash available; close=$634.62.

148. !May 27, 7:01 AMsignal

     Agent 5 — Dip Buyer (Evolving) — insufficient_capital

     Wanted to buy but only $22.31 cash available; close=$634.42.

149. ?May 27, 7:01 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

     Wanted to buy but only $21.36 cash available; close=$634.62.

150. !May 27, 7:01 AMsignal

     Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

     Wanted to buy but only $2.08 cash available; close=$634.42.

151. ?May 26, 6:01 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     With no negative news headlines or recent SEC filings to explain the ~16% drop from the 30-day high, the decline appears more likely driven by macro/sector rotation rather than company-specific deterioration. REGN is a fundamentally strong large-cap biotech with durable revenue streams (Dupixent, Eylea) and a solid balance sheet, suggesting no structural impairment. However, the macro backdrop shows elevated 10-year inflation expectations (~2.5σ above trend), which pressures long-duration growth assets like biotech, creating a headwind for a near-term rebound to the prior high.

152. ?May 26, 6:01 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $22.31 cash available; close=$634.42.

153. !May 26, 6:01 PMsignalseverity 0.17

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     With no negative news headlines or recent SEC filings to explain the ~16% drop from the 30-day high, the decline appears more likely driven by macro/sector rotation rather than company-specific deterioration. REGN is a fundamentally strong large-cap biotech with durable revenue streams (Dupixent, Eylea) and a solid balance sheet, suggesting no structural impairment. However, the macro backdrop shows elevated 10-year inflation expectations (~2.5σ above trend), which pressures long-duration growth assets like biotech, creating a headwind for a near-term rebound to the prior high.

154. ?May 26, 6:01 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

     Wanted to buy but only $2.08 cash available; close=$634.42.

155. ?May 26, 7:03 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $0.00 cash available; close=$638.88.

156. ?May 26, 7:02 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

     Wanted to buy but only $0.00 cash available; close=$638.88.

157. ?May 22, 6:01 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $5.71 cash available; close=$638.76.

158. ?May 22, 6:01 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     With no negative news headlines or recent SEC filings to explain the ~16% drop from the 30-day high, the decline appears more likely driven by macro/sector rotation rather than company-specific deterioration. REGN is a fundamentally strong large-cap biotech with durable revenue streams (Dupixent, Eylea) and a solid balance sheet, suggesting no structural impairment. However, the macro backdrop shows elevated 10-year inflation expectations (~2.5σ above trend), which pressures long-duration growth assets like biotech, creating a headwind for a near-term rebound to the prior high.

159. ?May 22, 6:01 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, diversified pipeline) with no confirmed negative fundamental catalyst visible in the evidence window — no filings, no headlines, no insider sales. The ~16% drop from the 30-day high appears sector-driven rather than idiosyncratic, as Health Care (XLV) is among the weakest sectors with -11.35pts 30d relative underperformance vs SPY, suggesting REGN is largely caught in a broader sector rotation/headwind. However, confirmation signals are entirely absent (no insider buys, no unusual call flow, no analyst upgrades), and macro headwinds are present with 10Y at 4.61% and elevated inflation expectations (T10YIE 2.5σ above trend), which are structural headwinds for long-duration biotech names.

160. ?May 22, 7:01 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $0.00 cash available; close=$642.59.

161. ?May 22, 7:01 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, diversified pipeline) with no confirmed negative fundamental catalyst visible in the evidence window — no filings, no headlines, no insider sales. The ~16% drop from the 30-day high appears sector-driven rather than idiosyncratic, as Health Care (XLV) is among the weakest sectors with -11.35pts 30d relative underperformance vs SPY, suggesting REGN is largely caught in a broader sector rotation/headwind. However, confirmation signals are entirely absent (no insider buys, no unusual call flow, no analyst upgrades), and macro headwinds are present with 10Y at 4.61% and elevated inflation expectations (T10YIE 2.5σ above trend), which are structural headwinds for long-duration biotech names.

162. ?May 21, 6:01 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $0.00 cash available; close=$642.44.

163. ?May 21, 6:00 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, diversified pipeline) with no confirmed negative fundamental catalyst visible in the evidence window — no filings, no headlines, no insider sales. The ~16% drop from the 30-day high appears sector-driven rather than idiosyncratic, as Health Care (XLV) is among the weakest sectors with -11.35pts 30d relative underperformance vs SPY, suggesting REGN is largely caught in a broader sector rotation/headwind. However, confirmation signals are entirely absent (no insider buys, no unusual call flow, no analyst upgrades), and macro headwinds are present with 10Y at 4.61% and elevated inflation expectations (T10YIE 2.5σ above trend), which are structural headwinds for long-duration biotech names.